RECOVER-2: Low Pressure Pneumoperitoneum and Deep Neuromuscular Block Versus Standard Laparoscopy During Robot Assisted Radical Prostatectomy to Improve the Quality of Recovery and Immune Homeostasis; Study Protocol for a Randomized Controlled Study.

Sponsor
Radboud University Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT04250883
Collaborator
Merck Sharp & Dohme LLC (Industry)
96
1
2
14.4
6.7

Study Details

Study Description

Brief Summary

Intra-abdominal pressure (IAP) needed to create sufficient workspace during laparoscopic surgery affects the surrounding organs with ischemia-reperfusion injury and a systemic immune response. This effect is related to postoperative recovery, pain scores, opioid consumption, bowel function recovery, morbidity and possibly mortality. In clinical practice standard pressures of 12-16mmHg are applied instead of the lowest possible IAP, but accumulating evidence shows lower pressure pneumoperitoneum (PNP) (6-8mmHg) to be non-compromising for sufficient workspace, when combined with deep neuromuscular blockade (NMB) in a vast majority of patients. Therefore, low impact laparoscopy, meaning low pressure PNP facilitated by deep NMB, could be a valuable addition to Enhanced Recovery After Surgery (ERAS) Protocols.

The use of low pressure PNP may also reduce hypoxic injury and the release of DAMPs and thereby contributing to a better preservation of innate immune function which may help to reduce the risk of infectious complications.

The participants will be randomly assigned to one of the experimental groups with low impact laparoscopy or one of the control groups with standard laparoscopy.

Condition or Disease Intervention/Treatment Phase
  • Other: Low intra-abdominal pressure
  • Other: Deep neuromuscular blockade (NMB)
  • Other: Standard intra-abdominal pressure
  • Other: Moderate neuromuscular blockade (NMB)
N/A

Detailed Description

Intra-abdominal pressure (IAP) needed to create sufficient workspace during laparoscopic surgery affects the surrounding organs with ischemia-reperfusion injury and a systemic immune response. This effect is related to postoperative recovery, pain scores, opioid consumption, bowel function recovery, morbidity and possibly mortality. Therefore, low impact laparoscopy, meaning low pressure PNP facilitated by deep NMB, could be a valuable addition to Enhanced Recovery After Surgery (ERAS) Protocols.

The use of low pressure PNP may also reduce hypoxic injury and the release of DAMPs and thereby contributing to a better preservation of innate immune function which may help to reduce the risk of infectious complications.

The participants will be randomly assigned to the experimental group 1: low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)); 8 mmHg IAP after trocar introduction for perfusion measurement or the experimental group 2: low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)); 12 mmHg IAP after trocar introduction for perfusion measurement, or control group 1: standard laparoscopy (standard pressure (12 mmHg) and moderate NMB (TOF 1-2)); 8 mmHg IAP after trocar introduction for perfusion measurement, or control group 2: standard laparoscopy (standard pressure (12 mmHg) and moderate NMB (TOF 1-2)); 12 mmHg IAP after trocar introduction for perfusion measurement.

ICG injection will take place with starting pressure to quantify parietal peritoneum perfusion, and a parietal peritoneal biopsy will be taken. At the end of surgery, a second parietal peritoneum biopsy will be taken.

NB: After introduction of the camera trocar, insufflation of carbon dioxide is titrated to an IAP of 8mmHg in group A and C, and 14 mmHg in group B and D. After placement of the last trocar the injection of ICG and video registration of peritoneum will take place, and a peritoneal biopsy will be taken. There after surgery will take place with an IAP of 14mmHg in the control groups (C and D), and an IAP of 8mmHg in the experimental groups (A and B). In the control groups (C and D)

Pre- and postoperative a few questionnaires will be taken and blood withdrawals to evaluate the quality of recovery, and the immune response.

Study Design

Study Type:
Interventional
Actual Enrollment :
96 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
RandomizedRandomized
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Low Pressure Pneumoperitoneum and Deep Neuromuscular Blockade Versus Standard Laparoscopy During RARP to Improve the Quality of Recovery and Immune Homeostasis; Study Protocol for a Randomized Controlled Study
Actual Study Start Date :
Dec 24, 2020
Actual Primary Completion Date :
Dec 9, 2021
Actual Study Completion Date :
Mar 7, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental group: Low Impact laparoscopy

low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)

Other: Low intra-abdominal pressure
8 mmHg

Other: Deep neuromuscular blockade (NMB)
Deep NMB (PTC1-2)

Active Comparator: Control group: Standard laparoscopy

standard laparoscopy (standard pressure (14 mmHg) and moderate NMB (TOF 1-2)

Other: Standard intra-abdominal pressure
14 mmHg

Other: Moderate neuromuscular blockade (NMB)
Moderate NMB (TOF 1-2)

Outcome Measures

Primary Outcome Measures

  1. Quality of recovery - 40 items questionnaire score (QoR-40) [at postoperative day 1]

    40 points (minimum: extremely poor quality of recovery) to 200 points (maximum: excellent quality of recovery)

  2. Immune response represented by IL-6 [at postoperative day 1]

    IL-6 response upon whole blood LPS stimulation

  3. Immune response represented by IL-10 [at postoperative day 1]

    IL-10 response upon whole blood LPS stimulation

  4. Perfusion index of the parietal peritoneum [From ICG injection, up to 20 seconds]

    calculated from the slope of ICG fluorescence intensity, and time to maximal intensity in seconds. (extracted from video registration).

Secondary Outcome Measures

  1. Quality of recovery - 40 items questionnaire score (QoR-40) [day 10 after surgery]

    40 points (minimum: extremely poor quality of recovery) to 200 points (maximum: excellent quality of recovery)

  2. Health status with short form survey (SF-36) [day 10 and 3 months after surgery]

    The lower the score the more disability. The higher the score the less disability.

  3. Chronic pain with McGill pain questionnaire (MPQ) [3 months after surgery]

    range from 0 (no pain) to 78 (severe pain)

  4. Pain score with VAS [During hospital stay up to 3 days]

    pain scores with VAS 0 (no pain) to 10 (severe pain)

  5. Analgesia use [During hospital stay up to 3 days]

    non-cumulative and cumulative opioid use per day in morphine equivalent

  6. PONV [During hospital stay up to 3 days]

    With PONV impact scale score o (no PONV) to 6 (extreme PONV)

  7. Hospital stay [from admission up to 3 days]

    length of hospital stay in days

  8. Postoperative recovery time [From day of surgery up to 3 days]

    time to reach discharge criteria in days

  9. Operating conditions [During operation for up to 8 hours]

    surgical conditions with L-SRS 0 (extremely poor work field) to 5 (excellent work field)

  10. Complications [Day of surgery untill 30days after surgery]

    postoperative complications scored by Clavien Dindo classification; grade 0 (no deviation from ideal) grade 5 (death of patient)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    • Age ≥ 18 years
  • Undergoing elective robot assisted radical prostatectomy (RARP)

  • Obtained informed consent

Exclusion Criteria:
  • Laparoscopic radical prostatectomy without robot assistance

  • Insufficient control of the Dutch language to read the patient information and to fill out de questionnaires

  • Neo-adjuvant chemotherapy

  • Chronic use of analgesics or psychotropic drugs

  • Use of NSAID's shorter than 5 days before surgery

  • Severe liver- or renal disease

  • Neuromuscular disease

  • Hyperthyroidism or thyroid adenomas

  • Deficiency of vitamin K dependent clotting factors or coagulopathy

  • Planned diagnostics or treatment with radioactive iodine < 1 week after surgery

  • Indication for rapid sequence induction

  • BMI >35kg/m2

  • Known of suspected hypersensitivity to ICG, sodium iodide, iodine, rocuronium or sugammadex

  • Use of medication interfering with ICG absorption as listed in the summary of product characteristics (SPC); anticonvulsants, bisulphite compounds, haloperidol, heroin, meperidine, metamizol, methadone, morphium, nitrofurantoin, opium alkaloids, phenobarbital, phenylbutazone, cyclopropane, probencid

Contacts and Locations

Locations

Site City State Country Postal Code
1 Canisius Wilhelmina ziekenhuis Nijmegen Netherlands

Sponsors and Collaborators

  • Radboud University Medical Center
  • Merck Sharp & Dohme LLC

Investigators

  • Principal Investigator: Michiel Warle, Dr., Radboud UMC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Radboud University Medical Center
ClinicalTrials.gov Identifier:
NCT04250883
Other Study ID Numbers:
  • NL72780.091.20
  • 2020-000411-79
First Posted:
Jan 31, 2020
Last Update Posted:
May 13, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 13, 2022